Acumen Pharmaceuticals earnings release, October 26, 2026

Acumen Pharmaceuticals, Inc. (ABOS) · Form 8-K, Item 2.02 · Filed · SEC filing

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

• Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in November 2026

• IND filing for the Enhanced Brain Delivery™ (EBD®)program lead clinical candidate targeted for mid-2027

• Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027

• Company to host conference call and webcast today at 8:00 a.m. ET

NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc.

(NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.

“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Another important piece of Acumen’s value proposition is our Enhanced Brain Delivery™ program, combining a validated blood-brain barrier-penetrating technology with an AβO-selective therapeutic antibody. We continue to make progress on IND-enabling activities in support of a mid-2027 IND submission for a lead candidate and remain encouraged about the potential it holds as a next-generation Alzheimer’s disease treatment.”

Anticipated Milestones

• The Company expects to report topline results from ALTITUDE-AD in November 2026.

◦ ALTITUDE-AD is a 3-arm Phase 2 study investigating sabirnetug in 542 participants (N=180 per arm) for the treatment of early Alzheimer’s disease.

◦ ALTITUDE-AD includes two active doses (35 mg/kg, 50 mg/kg, IV Q4W) vs. placebo over an 18-month double-blinded period.

◦ Topline results are expected to include the iADRS (Integrated Alzheimer’s Disease Rating Scale), our primary clinical efficacy endpoint, as well as key secondary endpoints, such as CDR-SB (Clinical Dementia Rating – Sum of the Boxes), certain safety measures such as adverse event rates, including ARIA rates, and key biomarkers.

• The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.

Third Quarter 2026 Financial Results

• Cash Balance.

As of Sept. 30, 2026, cash, cash equivalents and marketable securities totaled $78.6 million compared to cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026.

Cash is expected to support current clinical and operational activities into early 2027.

• Research and Development (R&D) Expenses.

R&D expenses were $21.1 million for the quarter ended Sept. 30, 2026, compared to $22.0 million for the quarter ended Sept. 30, 2025. The decrease was primarily due to reductions in manufacturing and materials costs, and CRO costs, which are both associated with our ALTITUDE-AD clinical trial, and partially offset by increased spending for our EBD program.

• General and Administrative (G&A) Expenses.

G&A expenses were $4.7 million for the quarter ended Sept. 30, 2026, compared to $4.5 million for the quarter ended Sept. 30, 2025.

• Loss from Operations.

Loss from operations was $25.8 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025. This decrease was due to the decreased R&D expenses over the prior year period.

• Net Loss.

Net loss was $25.4 million for the quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025.

Conference Call Details

Acumen will host a conference call and live audio webcast today, Oct. 26, 2026, at 8:00 a.m. ET.

To participate in the live conference call, please register using this link.

After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company’s website at www.acumenpharm.com.²

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early

AD.

About ALTITUDE-AD (Phase 2)

Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer’... (truncated)igative sites located in the United States, Canada, the European Union and the United Kingdom.

Topline results are expected in November 2026.

More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD®) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Financial statements

Income Statement

Three Months Ended September 30, — (unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating expensesResearch and development21,11321,96865,40684,359
Operating expensesGeneral and administrative4,7004,54514,11214,274
Operating expensesTotal operating expenses25,81326,51379,51898,633
Operating expensesLoss from operations-25,813-26,513-79,518-98,633
Other income (expense)Interest income8121,6392,9876,125
Other income (expense)Interest expense-999-1,068-3,162-3,137
Other income (expense)Change in fair value of embedded derivatives650-440950-290
Other income (expense)Other expense, net-19-69-81-262
Other income (expense)Total other income444626942,436
Other income (expense)Net loss-25,369-26,451-78,824-96,197
Other comprehensive gain (loss)Unrealized (loss) gain on marketable securities-1286-108157
Other comprehensive gain (loss)Comprehensive loss-25,381-26,365-78,932-96,040
Other comprehensive gain (loss)Net loss per common share, basic and diluted-0.35-0.44-1.14-1.59
Other comprehensive gain (loss)Weighted-average shares outstanding, basic and diluted72,321,45960,573,42569,297,15560,557,668

Balance Sheet

September 30, — (in thousands, except share and per share data)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assetsCash and cash equivalents53,07553,989
Current assetsMarketable securities25,52962,876
Current assetsPrepaid expenses and other current assets6,5305,387
Current assetsTotal current assets85,134122,252
Current assetsRestricted cash231231
Current assetsOther assets, long-term200350
Current assetsTotal assets85,565122,833
Current liabilitiesAccounts payable6,056554
Current liabilitiesAccrued clinical trial expenses8,45910,616
Current liabilitiesAccrued expenses and other current liabilities10,16810,072
Current liabilitiesDebt, short-term20,4048,765
Current liabilitiesTotal current liabilities45,08730,007
Current liabilitiesDebt, long-term5,86822,396
Current liabilitiesTotal liabilities50,95552,403
Stockholders’ equityCommon stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 72,327,320 and 60,575,369 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively76
Stockholders’ equityAdditional paid-in capital559,914516,803
Stockholders’ equityAccumulated deficit-525,286-446,462
Stockholders’ equityAccumulated other comprehensive (loss) income-2583
Stockholders’ equityTotal stockholders’ equity34,61070,430
Stockholders’ equityTotal liabilities and stockholders’ equity85,565122,833

Cash Flow

Nine Months Ended September 30, — (unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activitiesNet loss-78,824-96,197
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation3546
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense7,6267,433
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of premiums and accretion of discounts on marketable securities, net-198-919
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value of embedded derivatives-950290
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of right-of-use asset10493
Adjustments to reconcile net loss to net cash used in operating activities:Realized gain on marketable securities-6-17
Adjustments to reconcile net loss to net cash used in operating activities:Noncash interest expense1,048942
Changes in operating assets and liabilities:Prepaid expenses and other current assets-1,1431,205
Changes in operating assets and liabilities:Other long-term assets1142
Changes in operating assets and liabilities:Accounts payable5,502-4,966
Changes in operating assets and liabilities:Accrued clinical trial expenses-2,157-5,460
Changes in operating assets and liabilities:Accrued expenses and other liabilities961,066
Changes in operating assets and liabilities:Net cash used in operating activities-68,856-96,442
Cash flows from investing activitiesPurchases of marketable securities-40,823-38,056
Cash flows from investing activitiesProceeds from maturities and sales of marketable securities78,266145,827
Cash flows from investing activitiesPurchases of property and equipment-88
Cash flows from investing activitiesNet cash provided by investing activities37,443107,683
Cash flows from financing activitiesProceeds from private placement, net of offering costs35,441
Cash flows from financing activitiesRepayments of debt-4,987
Cash flows from financing activitiesProceeds from exercise of stock options19437
Cash flows from financing activitiesRepurchase of common shares to pay employee withholding taxes-149-73
Cash flows from financing activitiesNet cash provided by (used in) financing activities30,499-36
Cash flows from financing activitiesNet change in cash and cash equivalents and restricted cash-91411,205
Cash flows from financing activitiesCash and cash equivalents and restricted cash at the beginning of the period54,22035,859
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,”³

“anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, and Acumen’s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, Acumen’s plans to develop a candidate to treat Alzheimer’s Disease utilizing EBD technology, including its expectations with respect to timing for the submission of an IND, the potential of its EBD candidates and the potential for developing a best-in-class therapeutic candidate for people living with Alzheimer’s Disease. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.

CONTACTS:

Investors:

Alex Braun abraun@acumenpharm.com

Media:

ICR Healthcare

AcumenPR@icrhealthcare.com⁴

Acumen Pharmaceuticals, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)⁵

Acumen Pharmaceuticals, Inc.

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(unaudited)⁶

Acumen Pharmaceuticals, Inc.

Condensed Statements of Cash Flows

(in thousands)

(unaudited)⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Acumen Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.